Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2Active not recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 44Squamous Cell Carcinoma of Head and Neck 19Breast Neoplasms 18Lung Neoplasms 17Colorectal Neoplasms 15Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Small Cell Lung Carcinoma 9Recurrence 9Sarcoma 8Pancreatic Neoplasms 8Prostatic Neoplasms 7Advanced Solid Tumors 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Biliary Tract Neoplasms 5Mesothelioma, Malignant 4Lymphoma, Follicular 4Lymphoma 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4

Interventions

Radiotherapy 11Cisplatin 11Radiotherapy, Intensity-Modulated 6Radiation 5Fluorouracil 5Cetuximab 5pembrolizumab 4Carboplatin 3fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Vorinostat 2Surveys and Questionnaires 2Restraint, Physical 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Nivolumab 2Nicotine 2Immunohistochemistry 2Hydroxyurea 2Gene Expression Profiling 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Counseling 2Celecoxib 2Bupropion 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Oropharyngeal Neoplasms × durvalumab × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡